Antimicrobial resistance is a growing problem and one that is already claiming over a million lives per year. The situation is urgent but finding a sustainable solution is a difficult prospect ...

The pharmaceutical industry is at a pivotal juncture. While recent advancements in gene therapy and GLP-1 drugs signal the potential for significant growth, the sector faces challenges stemming ...

A pioneering clinical trial backed by the EU and drugmaker Takeda will look for biomarkers that could be used to identify people at risk of developing Crohn's disease in the hope of intervening ...

Commercial services player EVERSANA has joined the growing number of companies partnering with Veeva Systems – a specialist in cloud software for the life sciences industry – on the ...

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh discusses stem cell therapy, and accessibility to and affordability of such treatment, with Rafael E Carazo Salas, founder ...

Last month, the FDA granted approval to Eli Lilly’s donanemab - or Kisunla - for the treatment of Alzheimer’s disease. Its approval was based on the treatment demonstrating what the FDA ...

People with a form of severe epilepsy will now be able to get NHS access to a new drug from UCB, Fintepla, that could significantly reduce their seizures. The NHS will fund Fintepla (fenfluramine ...

Lipid nanoparticle (LNP) mRNA vaccines emerged during the COVID-19 pandemic to form an almost miraculous protection against a virus, which killed millions around the world. Aided by expedited ...

A key hurdle in front of the EU reforms to pharma legislation has fallen, after the European Parliament’s Environment, Public Health and Food Safety (ENVI) committee approved a series of ...

The critical need to improve prior authorisation processes might have reached its tipping point on the 17th January. That’s when the Biden administration announced its new mandate — the CMS ...

With the FDA and EMA releasing their annual reports detailing novel drug approvals in 2024, a new pharmaphorum podcast looks ...

Cambridge, Massachusetts-based Vor Bio has confirmed that it will halt clinical and manufacturing operations, including its ...